ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key products include ORTHOVISC (osteoarthritis), ophthalmic viscoelastics (AMVISC, CoEase, STAARVISC-II, ShellGel), and HYVISC (equine osteoarthritis). ORTHOVISC is marketed internationally but remains investigational in the U.S. pending FDA Pre-Market Approval (PMA).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Product revenue increased 26.9% in Q3 2003 and 19.0% for the nine months ended Sept 30, 2003, compared to the prior year. This was driven by increased sales of ORTHOVISC (international) and HYVISC (equine), partially offset by a decrease in sales to Bausch & Lomb.
• Profitability Improvement: The company reported a net income of $420,000 for Q3 2003, a significant turnaround from a net loss of $908,000 in Q3 2002. Gross margins expanded significantly due to improved manufacturing efficiencies and cost controls.
• Expense Reduction: Research and development expenses decreased 51.7% in Q3 2003, primarily due to the completion of the Phase III clinical trial for ORTHOVISC. Selling, general, and administrative expenses also declined slightly.
• Restatement Impact: The prior year (2002) results were restated in January 2003 to reverse $326,000 in revenue related to HYVISC sales made before regulatory approval of a new cleanroom. This restatement increased the reported loss for the comparable 2002 periods.

Guidance, Outlook, and Risks

• Deferred Revenue: Approximately $846,000 of revenue related to Bausch & Lomb sales is currently deferred. Management expects to recognize this in Q4 2003 if annual unit volume targets are not met, avoiding a cash rebate. If targets are met, the amount will be rebated.
• Regulatory Outlook: A PMA application for ORTHOVISC was submitted to the FDA in May 2003. Approval is required for U.S. commercial sales. The company also plans to initiate clinical trials for INCERT (surgical adhesions) and cosmetic tissue augmentation products in late 2003/2004.
• Liquidity: The company holds approximately $12.9 million in cash and equivalents. Management believes this is sufficient to fund operations for at least the next 12 months.
• Key Risks:
  • Customer Concentration: Four customers accounted for 89.5% of product revenue in the first nine months of 2003. Bausch & Lomb alone accounted for 45.4% of product revenue.
  • Regulatory Approval: Failure to obtain FDA approval for ORTHOVISC or future products would materially harm the business.
  • Stock Volatility: The stock price has been highly volatile, and there is a risk of delisting from NASDAQ if the bid price remains below $1.00 for 30 consecutive trading days.

Investor Verification Checklist

• Deferred Revenue Recognition: Verify the Q4 2003 recognition of the ~$846,000 deferred revenue from Bausch & Lomb and confirm whether a rebate was required.
• Customer Concentration: Monitor the stability of relationships with the top four customers, particularly Bausch & Lomb, which represents nearly half of product revenue.
• FDA PMA Status: Track the status of the ORTHOVISC PMA application submitted in May 2003, as U.S. commercialization depends entirely on this approval.
• Stock Price Compliance: Monitor the daily trading price to ensure it remains above the $1.00 threshold required to maintain NASDAQ listing.
• Restatement Resolution: Confirm that the re-released HYVISC inventory (previously withdrawn due to cleanroom approval issues) is being sold without further regulatory impediments.